MediWound today announced that the U.S. Department of War (DoW) has awarded it an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care.
The supplemental award raises the total program budget to $21.8 million. The program is intended to support development of the room-temperature-stable formulation through submission of an IND application to the FDA.
“A room-temperature-stable formulation of NexoBrid is designed to simplify storage and handling requirements and enable the use of non-surgical enzymatic debridement in battlefield and other austere settings, where access to surgical capabilities and cold-chain infrastructure may be limited,” said MediWound CEO Ofer Gonen in a statement. “This additional funding supports the next stage of development toward an IND submission. Our focus is now on completing CMC development, establishing in-house cGMP manufacturing capabilities, and producing clinical batches to support the clinical program.”
The room-temperature-stable NexoBrid development program is within the scope of MediWound’s existing North American license agreement with Vericel Corporation. Under the agreement, Vericel holds exclusive commercial and development rights to NexoBrid in North America.
